Pediatric Rheumatology Highlights

• Abstract 632: Predictors of Bone Mineral Density (BMD) in a Large Cohort of Children with Juvenile Idiopathic Arthritis
• Abstract: 222: Alendronate Treatment of Pediatric Patients with Connective Tissues Disorders. A Ten Year Follow-Up Study
• Abstract: 1282: Preliminary Evidence for Sustained Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-1 Inhibitor, In Systemic Juvenile Idiopathic Arthritis (SJIA)
• Abstract: 682: Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel®) Therapy in Patients With Juvenile Rheumatoid Arthritis
• Abstract: 681: Adalimumab is Safe and Effective During Long-Term Treatment of Patients with Juvenile Rheumatoid Arthritis: Results from a 2-Year Study
• Abstract 679: Efficacy of Abatacept in Different Sub-Populations of Juvenile Idiopathic Arthritis (JIA): Results of a Randomized Withdrawal Study
• Abstract: 680: Abatacept Treatment of Juvenile Idiopathic Arthritis (JIA): Safety Report

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.